Do Calcium Channel Blockers Increase the Diagnosis of Heart Failure in Patients With Hypertension?

被引:15
作者
Shibata, Marcelo C. [1 ]
Leon, Hernando [1 ,5 ]
Chatterley, Trish [2 ,4 ]
Dorgan, Marlene [2 ]
Vandermeer, Ben [3 ]
机构
[1] Univ Alberta, EPICORE Ctr, Div Cardiol, Edmonton, AB T6G 2M7, Canada
[2] Univ Alberta, John W Scott Hlth Sci Lib, Edmonton, AB T6G 2M7, Canada
[3] Univ Alberta, Alberta Res Ctr Child Hlth Evidence, Dept Pediat, Edmonton, AB T6G 2M7, Canada
[4] Univ Alberta, Inst Hlth Econ, Edmonton, AB T6G 2M7, Canada
[5] Univ Alberta, Dept Med, Gen Internal Med Program, Edmonton, AB T6G 2M7, Canada
关键词
CORONARY-ARTERY-DISEASE; ANTIHYPERTENSIVE THERAPIES; AMLODIPINE; OUTCOMES; NIFEDIPINE; MORBIDITY; MORTALITY; VERAPAMIL; TRIAL; METAANALYSIS;
D O I
10.1016/j.amjcard.2010.02.031
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Calcium channel blockers (CCBs) are widely used to control hypertension. Previous work suggested that their use could increase heart failure (HF), which is 1 of the consequences of uncontrolled hypertension. Information about the effect of CCBs on incident HF in patients with hypertension is scarce. A systematic review was conducted to evaluate patients with hypertension treated with CCBs and incident HF. An electronic search of publications was conducted using 8 major databases. Studies were eligible if they (1) were randomized clinical trials, (2) performed comparisons of CCBs versus active control, (3) randomized >200 patients, (4) had follow-up periods >6 months, and (5) provided data regarding incident HF. Trials of renal transplantation patients, placebo-controlled trials, and HF trials were excluded. A total of 156,766 patients were randomized to CCBs or control, with a total of 5,049 events. The analysis indicated a significant increase in the diagnosis of HF in patients allocated to CCBs (odds ratio 1.18, 95% confidence interval 1.07 to 1.31). The effect observed was independent of incident myocardial infarction. Subgroup analyses indicated that patients with diabetes were at higher risk for developing HF (odds ratio 1.71, 95% confidence interval 1.21 to 2.41). In conclusion, the results suggest that patients with hypertension treated with CCBs have increased incident HF. (C) 2010 Elsevier Inc. All rights reserved. (Am J Cardiol 2010;106:228-235)
引用
收藏
页码:228 / 235
页数:8
相关论文
共 30 条
  • [1] Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis - A randomized controlled trial
    Agodoa, LY
    Appel, L
    Bakris, GL
    Beck, G
    Bourgoignie, J
    Briggs, JP
    Charleston, J
    Cheek, D
    Cleveland, W
    Douglas, JG
    Douglas, M
    Dowie, D
    Faulkner, M
    Gabriel, A
    Gassman, J
    Greene, T
    Hall, Y
    Hebert, L
    Hiremath, L
    Jamerson, K
    Johnson, CJ
    Kopple, J
    Kusek, J
    Lash, J
    Lea, J
    Lewis, JB
    Lipkowitz, M
    Massry, S
    Middleton, J
    Miller, ER
    Norris, K
    O'Connor, D
    Ojo, A
    Phillips, RA
    Pogue, V
    Rahman, M
    Randall, OS
    Rostand, S
    Schulman, G
    Smith, W
    Thornley-Brown, D
    Tisher, CC
    Toto, RD
    Wright, JT
    Xu, SC
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (21): : 2719 - 2728
  • [2] Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetics
    Baba, S
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2001, 54 (03) : 191 - 201
  • [3] Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy
    Berl, T
    Hunsicker, LG
    Lewis, JB
    Pfeffer, MA
    Porush, JG
    Rouleau, JL
    Drury, PL
    Esmatjes, E
    Hricik, D
    Parikh, CR
    Raz, I
    Vanhille, P
    Wiegmann, TB
    Wolfe, BM
    Locatelli, F
    Goldhaber, SZ
    Lewis, EJ
    [J]. ANNALS OF INTERNAL MEDICINE, 2003, 138 (07) : 542 - 549
  • [4] Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) Trial
    Black, HR
    Elliott, WJ
    Grandits, G
    Grambsch, P
    Lucente, T
    White, WB
    Neaton, JD
    Grimm, RH
    Hansson, L
    Lacourcière, Y
    Muller, J
    Sleight, P
    Weber, MA
    Williams, G
    Wittes, J
    Zanchetti, A
    Anders, RJ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (16): : 2073 - 2082
  • [5] Final outcome results of the multicenter isradipine diuretic atherosclerosis study (MIDAS) - A randomized controlled trial
    Borhani, NO
    Mercuri, M
    Borhani, PA
    Buckalew, VM
    CanossaTerris, M
    Carr, AA
    Kappagoda, T
    Rocco, MV
    Schnaper, HW
    Sowers, JR
    Bond, MG
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (10): : 785 - 791
  • [6] Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT)
    Brown, MJ
    Palmer, CR
    Castaigne, A
    de Leeuw, PW
    Mancia, G
    Rosenthal, T
    Ruilope, LM
    [J]. LANCET, 2000, 356 (9227) : 366 - 372
  • [7] Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA):: a multicentre randomised controlled trial
    Dahlöf, B
    Sever, PS
    Poulter, NR
    Wedel, H
    Beevers, DG
    Caulfield, M
    Collins, R
    Kjeldsen, SE
    Kristinsson, A
    McInnes, GT
    Mehlsen, J
    Nieminen, M
    O'Brien, E
    Östergren, J
    [J]. LANCET, 2005, 366 (9489) : 895 - 906
  • [8] de Champlain Jacques, 2007, J Clin Hypertens (Greenwich), V9, P168
  • [9] Furberg CD, 2002, JAMA-J AM MED ASSOC, V288, P2981
  • [10] Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension:: the Nordic Diltiazem (NORDIL) study
    Hansson, L
    Hedner, T
    Lund-Johansen, P
    Kjeldsen, SE
    Lindholm, LH
    Syvertsen, JO
    Lanke, J
    de Faire, U
    Dahlöf, B
    Karlberg, BE
    [J]. LANCET, 2000, 356 (9227) : 359 - 365